Clinical Study of O&D-001 Injection in the Treatment of Relapsed or Refractory Multiple Myeloma

This study is a single-center, open and dose-escalation clinical study to evaluate the safety, tolerability, PK/PD characteristics and preliminary efficacy of the investigational drug O\&D-001 injection in the treatment of relapsed or refractory multiple myeloma.

Trial Details

NCT ID
NCT07369895
Phase
PHASE1
Sponsor
O&D BioTech Group CO., Limited
Status
RECRUITING
Cancer Type
Relapsed/Refractory Multiple Myeloma
Interventions
  • Chimeric antigen receptor T cell O&D-001 injection targeting BCMA and GPRC5D
Locations (sample)
  • Guangzhou, Guangdong, China|23.11667,113.25

Key Eligibility Criteria

  • Aged 18-75 years, inclusive, regardless of gender.
  • Subjects voluntarily agree to participate in this study, sign the informed consent form, and are willing to complete all trial procedures.
  • Meets the internationally accepted diagnostic criteria for multiple myeloma (IMWG Diagnostic Criteria 2016, Appendix 1).
  • Tumor specimen (bone marrow) from the subject tests positive for BCMA or GPRC5D expression on the myeloma cell membrane via immunohistochemistry (I…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Relapsed/Refractory Multiple Myeloma Trials on Trialify →